Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
This is a phase II, single-arm, multi-center study of neoadjuvant osimertinib in combination with chemotherapy for the treatment of patients with resectable EGFR-mutant stage III (N2) non-squamous non-small cell lung cancer
Non-Small Cell Lung Cancer
DRUG: Osimertinib|DRUG: Cisplatin|DRUG: Pemetrexed
complete lymph node clearance rate, the ratio of ypN0 percentage after resection, From date of enrollment to an average of 12 weeks after the first dose
Major Pathological Response (MPR), Defined as â‰¤10% residual cancer cells in the main tumour, as assessed per central pathology laboratory post-surgery, From date of enrollment to an average of 12 weeks after the first dose|Pathological complete response (pCR), Defined as absence of any residual cancer cells in the dissected tumour samples, including the main tumour and lymph nodes, assessed post-surgery, From date of enrollment to an average of 12 weeks after the first dose|Downstaging, Measured using pathologic mediastinal lymph node evaluation, From date of enrollment to an average of 12 weeks after the first dose|Disease free survival (DFS), DFS is defined as the time from the date of surgery until the first date of disease recurrence (local or distant) or date of death due to any cause, whichever occurs first., From date of enrollment up to approximately 42 months after date of resection
This is a phase II, single-arm, multi-center study of neoadjuvant osimertinib in combination with chemotherapy for the treatment of patients with resectable EGFR-mutant stage III (N2) non-squamous non-small cell lung cancer